Royan using stem cells to treat kidney diseases

Tehran, Dec 11, IRNA – Royan Institute researchers are conducting clinical trials to treat chronic and acute kidney disease by using mesenchymal stem cells, an official said.
  Speaking on the sidelines of the 12th Asian Congress of Urology (ACU), Dr. Reza Moqaddas-Ali, the head of Kidney Group of Stem Cells Research Center affiliated to Royan Institute, added that the researchers have conducted animal trials successfully.

“Results of animal trials showed that mesenchymal stem cell treatment has been found to be a good treatment for acute kidney injury,” he said.

“The treatment was not very effective in treating chronic kidney disease, but helps prevent progression of acute kidney injury to advanced chronic kidney disease.”

Chronic kidney disease, also known as chronic renal disease, is a progressive loss in renal function over a period of months or years.

Acute kidney injury (AKI) is an abrupt loss of kidney function that develops within seven days.

The ACU took place on Kish Island in southern Iran from December 5 to 9.

The Iranian Urological Association organized the event that featured lectures both by Asian and non-Asian experts, oral and poster presentations, live surgery sessions as well as workshops and an exhibition.

Mesenchymal stem cells are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells).



The Iran Project is not responsible for the content of quoted articles.